The European Society of Cardiology (ESC) recently updated its guidelines. Consequently, based on the EMPEROR-Preserved and DELIVER trials, the use of SGLT-2 inhibitors is now recommended for all stages of heart failure. Thus, in addition to HFrEF, HFmrEF and HFpEF are now class IA indications for dapagliflozin or empagliflozin. In clinical trials, the use of SGLT-2 inhibitors has significantly reduced hospitalizations due to heart failure in particular.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- HAUSARZT PRAXIS
